New Treatments Available For Metastatic Castrate-Resistant Prostate CancerWilliam J. Catalona
Prostate cancer is the second leading cause of cancer-related deaths among men in the United States with a five-year relative survival rate of near 100 percent when diagnosed early. Metastatic prostate cancer has a five-year survival rate of 30 percent. Current therapeutics like first- and next...
Metastatic colorectal cancer (CRC) is still in need of effective treatments. This study applies a holistic approach to propose new targets for treatment of primary and liver metastatic CRC and investigates their therapeutic potential in-vitro. An integrative analysis of primary and metastatic CRC sampl...
The results of the study have been satisfactory and, for this reason, the team wants to conduct a clinical trial to assess the safety and efficacy of this combination in patients with prostate cancer resistant to docetaxel. Vicenç Ruiz de Porras and Adrià Bernat-Peguera, ICO-IGTP researchers...
“We can’t cure the vast majority of patients who present with metastatic prostate cancer. So, the goal then is to control the disease. So, once patients become castration-resistant, the number of treatments we use, unfortunately, are not able to provide as durable remissions,” he says....
doi:10.1038/nrurol.2013.232Grivas, Petros D.Keller, Evan T.Nature Reviews UrologyPetros D.Grivas, Evan T.Keller. (2013) Prostate cancer: Radium-223: a new treatment option for bone-metastatic CRPC. Nature Reviews Urology 10 , 630-631 /...
Adding docetaxel or abiraterone to ADT improves metastatic prostate cancer survival, with patient and cost factors the most important considerations when choosing between them, say guidelines.
Modulation of the Activity of Sp Transcription Factors by Mithramycin Analogues as a New Strategy for Treatment of Metastatic Prostate Cancer Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One 7, ......
New treatments for metastatic kidney cancer Renal cell carcinoma accounts for approximately 3% of adult malignancies and 90%-95% of neoplasms arising from the kidney. It is characterized by a lack of early warning signs, diverse clinical manifestations, resistance to radiation and... A Mancuso,CN...
Prostate cancer cells. Credit: NIH Image Gallery Survival rates for men with metastatic prostate cancer have increased by an average of six months, something which coincides with the gradual introduction of "dual treatment" since 2016. This is according to a register study of all Swedish men diag...